DUBLIN, Ireland and CHICAGO, April 25, 2022 (GLOBE NEWSWIRE) — Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next-generation oral and IV antibiotics to treat infections caused by drug-resistant pathogens in community and hospital settings, today announced two poster presentations at the 32n/a European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) to be held April 23-26, 2022 in Lisbon, Portugal.
The poster presentations at ECCMID were as follows:
- Title: In vitro Activity of sulopenem and comparators against anaerobic clinical isolates from the 2018-2020 SENTRY surveillance program
Speaker: steven aronin
Poster session: 5a. Mechanisms of action, new compounds, preclinical data & pharmacology of antibacterial agents
- Title: Efficacy and safety of intravenous sulopenem followed by oral sulopenem etzadroxil/probenecid compared with intravenous ertapenem followed by oral ciprofloxacin and metronidazole or amoxicillin-clavulanate in the treatment of complicated intra-abdominal infections: the SURE-3 trial
Speaker: steven aronin
Poster session: 5c. New or repurposed antibacterial agents: clinical trials
These posters can be viewed on the Company’s website atPublications: posters and presentationsunder the “Our Science” tab.
About Iterum Therapeutics plc
Iterum Therapeutics plc is a clinical-stage pharmaceutical company dedicated to the development of differentiated anti-infectives aimed at tackling the global crisis of multidrug-resistant pathogens to dramatically improve the lives of people affected by serious and life-threatening diseases around the world. . Iterum is currently advancing its first compound, sulopenem, a novel penem anti-infective compound, into phase 3 clinical development with an oral formulation. Sulopenem also has an IV formulation. Sulopenem has demonstrated potent in vitro activity against a wide variety of gram-negative, gram-positive, and anaerobic bacteria resistant to other antibiotics. Iterum has received Qualified Infectious Disease Product (QIDP) and Fast Track designations for its oral and IV formulations of sulopenem in seven indications. For more information, please visit http://www.iterumtx.com.
This press release contains forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding the development, therapeutic and commercial potential of sulopenem. In some instances, forward-looking statements may be identified by words such as “may”, “believe”, “intend”, “seek”, “anticipate”, “plan”, “estimate”, “will expects”, “should”, “assumes”, “continues”, “could”, “would”, “will”, “future”, “potential” or the negative form of these similar terms and expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause Iterum’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. forward-looking statements. Forward-looking statements include all matters that are not historical facts. Actual future results may differ materially from what is expected due to factors largely beyond Iterum’s control, including the uncertainties inherent in initiating and conducting clinical and non-clinical development, including any trials potential additional clinical and non-clinical development that may be conducted in response to the full response letter received by Iterum in July 2021, the availability and timing of data from this potential clinical and non-clinical development, changes in regulatory requirements or rulings regulatory authorities, the timing or likelihood of regulatory filings and approvals, including any potential resubmission of the new drug application for oral sulopenem, changes in public policy or legislation, plans and time to market , if oral sulopenem is approved, the actions of organi clinical research stations, suppliers and third party manufacturers, the accuracy of Iterum’s expectations regarding how far into the future Iterum c available ashes will fund Iterum’s ongoing operations, including the completion of clinical development and potential additional non-clinical use of oral sulopenem, the impact of COVID-19 and related accommodations, Iterum’s ability to maintain its listing on the Nasdaq stock market, risks and uncertainties regarding the outcome, impact, the effects and results of Iterum’s evaluation of corporate, strategic, financial and financing alternatives, including the terms, timing, structure, value, benefits and costs of any corporate alternatives, strategic, financial or funding and Iterum’s ability to achieve any at all and other factors discussed under “Risk Factors” in its Annual Report on Form 10-K filed with of the Securities and Exchange Commission (the “SEC”) on March 28, 2022, and other documents filed with the SEC from time to time. Forward-looking statements represent Iterum’s beliefs and assumptions only as of the date of this press release. Except as required by law, Iterum undertakes no obligation to publicly update these forward-looking statements, or to update the reasons why actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.